{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-009489","form_type":"8-K","ticker":"CLB","cik":"0001958086","company_name":"Core Laboratories Inc. /DE/","filed_at":"2024-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.373051+00:00","generated_at":"2026-06-06T14:12:45.282141+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Core Lab Q4 revenue $128.2M (+2% seq); EPS ex-items $0.19 (-14% seq); FY EPS +40%","bullets":["Q4 revenue $128.2M (+2% sequentially); GAAP EPS $0.14, ex-items EPS $0.19 (down 14% seq).","Q4 operating income ex-items $15.0M (12% margins); free cash flow $16.7M; debt cut $15M (8%).","Full year revenue $510.0M (+4% YoY); operating income ex-items $61.2M (+36%); EPS ex-items $0.80 (+40%).","Quarterly cash dividend $0.01/share, record Feb 12, payable Mar 4, 2024.","Effective tax rate impacted by non-cash deferred tax adjustments from U.S. domestication."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-009489","json":"https://secwatch.observer/filing/0000950170-24-009489.json","markdown":"https://secwatch.observer/filing/0000950170-24-009489.md","text":"https://secwatch.observer/filing/0000950170-24-009489.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958086/000095017024009489/0000950170-24-009489-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958086/000095017024009489/clb-20240131.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T14:12:45.282141+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9934a0bbb0d84b0b3f45cc7d272f75e34890f2e7","claim":"Core Laboratories Inc. /DE/ reported year ending December 31, 2023 results: revenue $510.0 million, EPS $0.86.","evidence_excerpt":"• FOURTH QUARTER FREE CASH FLOW OF $16.7 MILLION • FOURTH QUARTER DEBT REDUCED BY $15.0 MILLION OR OVER 8% • COMPANY ANNOUNCES Q1 2024 QUARTERLY DIVIDEND • FULL YEAR REVENUE OF $510.0 MILLION, UP 4% • FULL YEAR OPERATING INCOME OF $54.6 MILLION; EX-ITEMS, $61.2 MILLION, UP 36% • FULL YEAR GAAP EPS OF $0.86; EX-ITEMS, EPS OF $0.80, UP 40% HOUSTON (January 31, 2024) -","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1958086/000095017024009489/0000950170-24-009489-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ending December 31, 2023"},{"label":"Revenue","value":"$510.0 million"},{"label":"EPS","value":"$0.86"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a215c7d5ccd9c31943fc74b14437679b017ae45a","claim":"Core Laboratories Inc. /DE/ reported fourth quarter of 2023 results: revenue $128,200,000, EPS $0.14.","evidence_excerpt":"31, 2023. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS FOURTH QUARTER AND FULL YEAR 2023 RESULTS: • FOURTH QUARTER REVENUE OF $128.2 MILLION, UP 2% SEQUENTIALLY • FOURTH QUARTER OPERATING INCOME OF $14.6 MILLION; EX-ITEMS, $15.0 MILLION, DOWN 6% SEQUENTIALLY • FOURTH QUARTER OPERATING MARGINS, EX-ITEMS, OF 12% •","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1958086/000095017024009489/0000950170-24-009489-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter of 2023"},{"label":"Revenue","value":"$128,200,000"},{"label":"EPS","value":"$0.14"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}